Table 1.
Epidemiological estimates used to calculate the national analytic patient cohort.
| Parameter | Estimate | Reference |
|---|---|---|
| New lung cancer cases diagnosed in US in 2015 | 221,200 | [15] |
| % Lung cancer cases that are NSCLC | 85% | [16] |
| % NSCLC that are adenocarcinoma, large cell, or unspecified histology | 73% | [16] |
| % NSCLC advanced or metastatic at diagnosis (Stage IIIb or IV) | 58% | [16] |
| Diagnosed Cohort | 79,608 | |
| % Diagnosed patients tested for EGFR mutation in US | 76% | [17] |
| National Analytic Cohort | 60,502 | |
| Prevalence of EGFR mutation in US | 19% | [16] |
NSCLC = Non-small cell lung cancer; EGFR = Epidermal growth factor receptor.